Most Recent

image: Cancer Kismet

Cancer Kismet

By | April 1, 2015

Fate mapping allows researchers to follow cancer progression from its cell type of origin.

1 Comment

image: Control ALT, Delete Cancer

Control ALT, Delete Cancer

By , and | April 1, 2015

Fate mapping allows researchers to follow cancer progression from its cell type of origin.

1 Comment

image: Getting Your Sugar Fix

Getting Your Sugar Fix

By | April 1, 2015

Fate mapping allows researchers to follow cancer progression from its cell type of origin.

1 Comment

image: Setbacks and Great Leaps

Setbacks and Great Leaps

By | April 1, 2015

Fate mapping allows researchers to follow cancer progression from its cell type of origin.

1 Comment

image: Signaling Resistance

Signaling Resistance

By | April 1, 2015

Fate mapping allows researchers to follow cancer progression from its cell type of origin.

0 Comments

image: Toggling Between Life and Death

Toggling Between Life and Death

By | April 1, 2015

Fate mapping allows researchers to follow cancer progression from its cell type of origin.

0 Comments

image: Yvonne Saenger: Immunotherapy Pioneer

Yvonne Saenger: Immunotherapy Pioneer

By | April 1, 2015

Fate mapping allows researchers to follow cancer progression from its cell type of origin.

5 Comments

image: From Many, One

From Many, One

By | April 1, 2015

Fate mapping allows researchers to follow cancer progression from its cell type of origin.

4 Comments

image: Resisting Cancer

Resisting Cancer

By | April 1, 2015

Fate mapping allows researchers to follow cancer progression from its cell type of origin.

7 Comments

image: Short, Strong Signals

Short, Strong Signals

By | March 25, 2015

Fate mapping allows researchers to follow cancer progression from its cell type of origin.

0 Comments

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech